May 11, 2020 / 1:14 PM / 20 days ago

BRIEF-Crispr Therapeutics And Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted To Ctx001™ For The Treatment Of Severe Hemoglobinopathies

May 11 (Reuters) - CRISPR Therapeutics AG:

* CRISPR THERAPEUTICS AND VERTEX PHARMACEUTICALS ANNOUNCE FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO CTX001™ FOR THE TREATMENT OF SEVERE HEMOGLOBINOPATHIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below